Spruce Biosciences
SPRB
29 hedge funds and large institutions have $6.41M invested in Spruce Biosciences in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 8 closing their positions.
800% more call options, than puts
Call options by funds: $9K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less funds holding
Funds holding: 37 → 29 (-8)
26% less capital invested
Capital invested by funds: $8.61M → $6.41M (-$2.2M)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$119K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$28.3K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$23.7K |
| 4 |
SC
Shay Capital
New York
|
+$12.2K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.72K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$781K |
| 2 |
ACM
Altium Capital Management
New York
|
-$420K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$200K |
| 4 |
6CM
683 Capital Management
New York
|
-$73K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$64.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $1.01K | – | – | – |
|
|
CSC
27
Caldwell Sutter Capital
Sausalito,
California
| $475 | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $106 | +$37 | +1 | +50% |
|
29
JP Morgan Chase
New York
| $33 | – | – | – |
|
|
30
UBS Group
Zurich,
Switzerland
| $6 | -$64.4K | -1,759 | Closed |
|
|
RA
31
Rosalind Advisors
Toronto,
Ontario, Canada
| – | -$781K | -20,112 | Closed |
|
|
ACM
32
Altium Capital Management
New York
| – | -$420K | -10,816 | Closed |
|
|
ECM
33
ExodusPoint Capital Management
New York
| – | -$200K | -5,156 | Closed |
|
|
6CM
34
683 Capital Management
New York
| – | -$73K | -1,879 | Closed |
|
|
SCM
35
Superstring Capital Management
New York
| – | -$40.4K | -1,040 | Closed |
|
|
PFMU
36
Privium Fund Management (UK)
London,
United Kingdom
| – | -$12.9K | -327 | Closed |
|
37
Charles Schwab
San Francisco,
California
| – | -$7.92K | -204 | Closed |
|
38
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$1 | – | – |
|
SPRB Hedge Fund Activity: Q3 2024 in Review
29 of the 6,970 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q3 2024, worth a combined $6.41M — down 26% from $8.61M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of SPRB and 0 opened new positions — a net loss of 8 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $119K. The largest seller was Rosalind Advisors, exiting entirely with an estimated $781K sold.
- 29 institutional investors held Spruce Biosciences (SPRB) as of Q3 2024, down from 37 in Q2 2024.
- Funds reported $6.41M of Spruce Biosciences stock for Q3 2024, down 26% quarter-over-quarter.
- 0 funds opened new Spruce Biosciences positions in Q3 2024 and 8 closed out, a net change of -8 holders.
- The largest Spruce Biosciences buyer in Q3 2024 was Renaissance Technologies, an estimated $119K added.
- The largest Spruce Biosciences seller in Q3 2024 was Rosalind Advisors, an estimated $781K sold.
Based on aggregated 13F filings for Q3 2024.